Basel, December 6, 2013- Novartis today announced that results of a Phase III trial of the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival (PFS) in patients with relapsed or relapsed and refractory multiple myeloma when compared to bortezomib plus dexamethasone alone.
Basel, December 5, 2013 - Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company's innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company's Malaria Initiative.
Basel, December 4, 2013 - Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
Basel, November 29, 2013- Today's symposium of the Novartis Foundation for Sustainable Development (NFSD) convenes experts to discuss "What does it take to eliminate a disease?"
Basel, Switzerland, November 28, 2013- Novartis scientists have discovered a new drug target for treating malaria. The discovery, which is published online in the journal Nature,[2] identifies phosphatidylinositol-4 kinase (PfPI4K) as the target of the imidazopyrazines, a novel experimental antimalarial compound class that inhibits the development of multiple malaria-causing Plasmodium species at each stage of infection in the human host.
Basel, November 22, 2013 - Novartis today announced the launch of a USD 5 billion share buyback, reflecting the company's confidence in its long-term growth prospects, as well as its commitment to deliver strong shareholder returns.
Basel, Switzerland, November 15, 2013 - The World Forum for Ethics in Business (WFEB) awarded Novartis the Ethics in Business Award in the Outstanding Corporation category.
Basel, November 14, 2013- In recognition of Novartis' significant on-going contributions to malaria control and elimination, the company has been honored with the Global Corporate Citizenship Award at the Malaria No More International Honors annual benefit.
Basel, Switzerland, November 14, 2013 - Novartis announced today interim results from a Phase 1 clinical trial with its proprietary cell culture vaccine for the H7N9 avian influenza virus involving 400 healthy volunteers (18-64 years of age).
Basel, November 11, 2013 - Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for USD 1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.
